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Use of the tuberculin skin test (TST) for diagnosis of latent tuberculosis infection (LTBI)
among individuals who received the Bacille Calmette-Guérin (BCG) vaccine is complicated
by its potential cross-reaction with TST antigens which may cause false-positive results and
lead to patient and physician reluctance to initiate LTBI treatment. QuantiFERON1-TB Gold
(QFT-G) lacks this cross-reaction. We sought to study the impact of implementing QFT-G
testing in 2006 on LTBI treatment initiation and completion at NYC chest clinics.
Methods
QFT-G results from 10/2006–12/2008 in NYC Department of Health and Mental Hygiene
chest clinics were obtained from the electronic medical record system. The proportions of
patients who initiated and completed treatment among patients tested with QFT-G were
compared to those tested with TST from 10/2004–9/2006.
Results
Among 36,167 patients tested with QFT-G, 2,300 (6%) tested positive, 33,327 (93%) tested
negative, and 540 (1%) had an indeterminate result. Among those who had a positive QFT-
G test and deemed eligible, 985 (80%) initiated LTBI treatment and 490 (40%) completed
treatment. Historically, among patients tested with TST, 7,073 (19%) tested positive
(p<0.0001 compared to QFT-G); 3,182 (79%) of those eligible initiated LTBI treatment and
1,210 (30%) completed treatment (p<0.0001 compared to QFT-G).
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Conclusions
QFT-G implementation increased the proportion of patients completing LTBI treatment.
Additional studies are needed in more settings to determine whether using QFT-G leads to
a sustained increase in treatment completion.
Introduction
Tuberculosis (TB) rates have declined in the United States (US) since the late 1990s as the HIV
epidemic waned in addition to improvements in TB control infrastructure [1]. However, TB
elimination is far from being achieved, partly due to the large reservoir of individuals with
latent TB infection (LTBI). A key component of the US’s TB elimination strategy is the identifi-
cation and treatment of those at highest risk of developing TB including immunosuppressed
persons, recent immigrants to the US with LTBI, and contacts of known TB cases [1–3]. In the
US an estimated 4.2% of people are infected with TB [4].
For LTBI treatment to be an effective strategy for achieving TB elimination, a sizeable pro-
portion of those with LTBI must complete a 3–9 month treatment regimen. A large North
American multisite study of LTBI screening and treatment found that only 46.6% of those test-
ing TST positive completed treatment [5], a proportion that has remained unchanged during
the last decade [6]. Shorter LTBI treatment regimens have been recommended, and may be
associated with increased treatment completion [7–10].
Barriers to initiation and completion of LTBI treatment include provider and patient mis-
perceptions about LTBI and TB disease risk, as well as patients with LTBI doubting the accu-
racy of diagnostic tests such as the TST. In addition, therapy duration and potential drug
adverse events may also play a role in poor treatment initiation and adherence rates [11,12].
The medical training and background of healthcare providers can also affect their perception
of diagnostic accuracy and disease risk and whether they recommend treatment [13]. Further-
more, directly observed therapy (DOT), which can greatly improve treatment adherence, is not
standard for LTBI treatment as it is for active TB.
Due to the specific mixture of antigens used in the TST [14], individuals who have received
Bacillus Calmette-Guérin (BCG) vaccination or are infected with non-tuberculosis mycobacte-
ria (NTM) may have a false-positive TST result. Interferon-gamma release assays (IGRAs)
overcome some of the TST’s shortcomings by usingMycobacterium tuberculosis (M. tb) com-
plex-specific antigens that do not cross-react with BCG or with most NTMs.
Improved specificity of IGRAs may result in increased LTBI treatment initiation and com-
pletion. In a study conducted among healthcare workers, IGRA testing was associated with
increased initiation of LTBI treatment [15]. Use of IGRAs in the public health setting show
mixed results. In a recent study of contacts to TB cases, those with a positive IGRA were more
likely to both initiate and complete LTBI treatment compared to those who with a positive TST
[16]. However, in another study among patients with suspected LTBI, IGRA testing was not
associated with treatment initiation or completion [17]. The objective of our study was to eval-
uate the impact of utilizing QuantiFERON1-TB Gold (QFT-G) on LTBI treatment initiation
and completion at NYC Department of Health and Mental Hygiene (DOHMH) chest clinics.
Methods
Study subjects and data collection
In October 2006, the NYC DOHMH began implementing QFT-G (Cellestis Limited, Carnegie,
Victoria, Australia) as the standard test forM. tb infection for all patients aged1 year at its
LTBI Treatment: QFT-G vs. TST
PLOSONE | DOI:10.1371/journal.pone.0138349 September 15, 2015 2 / 12
Funding: This work was supported by New York City
Department of Health and Mental Hygiene program
funds. JK was supported by a T32 training grant
(5T32AI049821) during the period of this work. The
funders had no role in study design, data collection
and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: Cellestis paid for portions of T.
G.H.’s travel to three US-based conferences from
2009-10 where she was invited to present on NYC's
use of QFT-G. The author did not receive honoraria
for these presentations. This does not alter the
authors' adherence to PLOS ONE policies on sharing
data and materials.
chest clinics. At the time, the clinics provided testing for contacts of TB cases, other high-risk
individuals, and for those needing testing to satisfy administrative requirements (e.g. employ-
ment, school). These clinics also provided evaluation, medical care, and treatment for LTBI
and active TB [18]. The study population included patients who were tested with QFT-G at
any of the 10 DOHMH chest clinics from October 1, 2006−December 31, 2008. This group was
compared to a historical cohort of patients tested with TST at the same clinics from October 1,
2004−September 30, 2006.
QFT-G testing was performed and interpreted as positive, negative, or indeterminate, per
the FDA-approved package insert and the US Centers for Disease Control and Prevention
(CDC) guidelines [19,20]. TSTs were performed using the Mantoux method. Results were
interpreted by trained staff 48–72 hours later as positive or negative based on American Tho-
racic Society (ATS)/CDC guidelines [21]. Patients with a positive result or those at high risk for
developing TB disease (e.g., HIV-infected) were referred for chest radiograph and evaluation
by a physician.
LTBI diagnosis was based on the QFT-G or TST result, chest radiograph(s), physical exami-
nation, TB risk factor and exposure history, and, in certain circumstances, sputum examina-
tions [21,22]. After ruling out TB disease, the evaluating physician determined whether
treatment for LTBI was indicated in accordance with national guidelines and the NYC TB Clin-
ical Policies and Procedures [22–24]. The standard LTBI treatment regimen was 9 months of
isoniazid; alternative regimens were used as appropriate [22,25].
All data used in the study were abstracted from the clinic electronic medical record (EMR)
system. Available demographic information included birth date, sex, race/ethnicity, country of
birth, primary language, time in the US (foreign-born patients only) and reason for testing. We
categorized the reason for test as contact/non-contact; this did not affect the overall estimates
of test type (not shown).
Patients who had TB disease or who had a documented history of TB disease were excluded
from all analyses, as were patients who received both a QFT-G and TST test. For patients with
multiple tests of the same type, only the last result (and its associated clinical and demographic
characteristics) was used because most of these patients were contacts receiving a window and
post-window test and the last test was considered the final result. In addition, patients with a
positive test who had a documentation of a chest radiograph and a medical evaluation in the
EMR were considered fully evaluated. Patients missing either a chest radiograph or a medical
evaluation were considered to be partially evaluated. If neither existed, the patient was catego-
rized as not evaluated.
Statistical analysis
For each time period (QFT-G and TST), the percentages of individuals who had a positive test,
received a complete evaluation following a positive test, had an indication for LTBI treatment
as determined by a clinic physician, started on LTBI treatment, and completed LTBI treatment
were calculated. Comparisons between the time periods were conducted using Pearson’s chi-
square statistic.
The proportion of patients initiating LTBI treatment was calculated as the number of
patients with a positive test (QFT-G or TST) who initiated treatment divided by the number
with a positive test and an indication for treatment. Bivariate and multivariate Poisson regres-
sion models were used to determine whether the percentage of patients that started LTBI treat-
ment differed during the QFT-G and TST periods. Generalized Estimating Equations (GEE)
were used to account for similarities between patients tested at the same clinic. Any patient
whose final QFT-G result was indeterminate or missing or whose final TST result was not read
LTBI Treatment: QFT-G vs. TST
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were excluded from this analysis. Potential confounders evaluated included the following:
recent exposure to an active TB case (i.e. being a contact), age at testing, sex, birth in the US,
time in the US among foreign-born, primary language, and race/ethnicity. Unadjusted risk
ratios (RR) were first estimated for each variable and then adjusted models were constructed
with factors with a p-value<0.2 as well as year of test to account for any temporal changes in
LTBI treatment initiation and completion during the study period including other programs
initiated by the NYC DOHMH aimed at increasing LTBI treatment completion.
The proportion completing LTBI treatment was calculated by dividing the number of
patients completing treatment by either (a) the number of patients with an indication for treat-
ment or (b) those with indication who initiated treatment. An analysis similar to the one
described above was conducted for completion of LTBI treatment. Patients who did not have a
documented treatment outcome (TST: 987, QFT-G: 200) were assumed to have not completed
treatment.
All analyses were performed using SAS version 9.2 (SAS Institute, Cary, NC, USA).
Ethics Statement
The New York City Department of Health and Mental Hygiene Institutional Review Board
approved the study. No patient consent was obtained for this study as a waiver was received
from the aforementioned IRB.
Results
LTBI testing and treatment outcomes
From October 1, 2006−December 31, 2008, 38,372 patients were tested with QFT-G at the 10
chest clinics and from October 1, 2004−September 30, 2006, 40,752 patients received 43,978
TST implants (Fig 1A). There were 2,205 patients who received both tests and were excluded
(96% tested negative on both QFT-G and TST). Among patients tested only with QFT-G, 0.5%
(185/38,372) had multiple tests performed and during the TST period, 8% (3,226/43,978) had
>1 TST implanted; for these patients the last result was used. The percentage was substantially
higher for TST because it reflects patients not returning in 48–72 hours for the TST reading
and needing to be tested again. The baseline patient characteristics by LTBI time period are
shown in Table 1. Of the final 36,167 patients (38,372 minus 2,205 receiving both tests) in the
QFT-G time period, 33,327 (92%) tested negative, 2,300 (6%) tested positive, and 540 (2%) had
an indeterminate result. Of the final 38,547 patients tested with TST, 27,532 (71%) tested nega-
tive, 7,073 (18%) tested positive, and 3,942 (10%) did not return for the reading and did not
have another TST during the study period (Fig 1A). Overall, the percent that tested positive
with QFT-G was significantly lower than that with TST (6% vs. 18%, p<0.0001, Fig 1B).
Among the 2,300 individuals who tested QFT-G positive, 1,677 (73%) had a complete clini-
cal evaluation, and 1,230 (73%) of these individuals had an indication for treatment. Among
the 7,073 who tested positive with TST during the historical comparison period, 5,847 (83%)
had a full clinical evaluation and 4,017 (69%) of these fully evaluated patients had an indication
for treatment. Patients who tested positive with QFT-G were significantly more likely to have
an indication for treatment compared to those tested with TST (73% vs. 69%; p = 0.002;
Fig 1A).
Among patients who had an indication for LTBI treatment, 80% (985/1,230) in the QFT-G
period and 79% (3,182/4,017) initiated treatment in the TST period. This was not statistically
significant in the bivariate analysis (RR = 1.01, 95% CI = 0.98–1.10) but became significant
after adjusting for other covariates [adjusted RR (aRR) = 1.10, 95% CI = 1.03–1.17]. The rea-
sons and frequencies for not starting treatment despite indication were not statistically
LTBI Treatment: QFT-G vs. TST
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different between the TST and QFT-G time periods (overall P = 0.243). The most common rea-
sons for not starting treatment included refusal (QFT-G: 53%, TST: 55%); loss to follow-up or
moving (QFT-G: 31%, TST: 25%); no reason provided in the EMR (QFT-G: 8%, TST: 9%); or
other reasons including transferring to another healthcare provider (QFT-G: 6%, TST: 8%).
Among those with an indication for treatment, patients in the QFT-G period were 32%
more likely to complete treatment compared to the TST period (RR = 1.32, 95% CI = 1.16–
1.51; Table 2). After adjusting for other covariates, patients from the QFT-G period were 75%
more likely to complete treatment (aRR = 1.75, 95% CI = 1.49–2.06). Among those who initi-
ated treatment, those tested with QFT-G were 60% more likely to complete than the TST
group (aRR = 1.60, 95% CI = 1.36–1.87). In addition, younger patients as well as foreign-born
and non-English speakers were more likely to complete treatment compared to older, US-born
and English speaking patients respectively. Contacts were more likely to complete treatment
than non-contacts (aRR = 1.35, 95% CI = 1.14–1.52).
To examine whether the analysis of treatment initiation was affected by excluding those
without documentation of having a complete evaluation, we re-ran the analysis including these
patients. With the inclusion of these patients, QFT-G testing was not associated with increased
initiation (aRR = 1.06, 95% CI = 0.99–1.13). When these patients were included in the analysis
of treatment completion those tested with QFT-G remained more likely to complete among
patients with indication for treatment (aRR = 1.68, 95% CI = 1.40–2.02) and patients who
started treatment (aRR = 1.60, 95% CI = 1.33–1.90).
Discussion
The utilization of QFT-G in NYC DOHMH clinics was associated with several important
changes related to LTBI diagnosis and treatment. First, during the initial 2 years of its use, the
number of patients diagnosed with LTBI declined by 68% from 18% when TST was used to 6%
with QFT-G. This finding is consistent with other studies of QFT-G and with QFT-G being a
more specific test than the TST in populations that have received BCG [15,26–28] and have a
low risk of TB infection. Second, the percentage of patients completing LTBI treatment among
those with indication increased significantly from 30% to 40% compared to when TST was
used. Our finding of a 40–50% completion rate among treatment initiators is consistent with
other studies of LTBI treatment with TST and IGRAs, and illustrates the challenges posed by
LTBI treatment, including long treatment duration, associated side effects, and treatment of an
asymptomatic condition [29–32].
Our findings indicate that using IGRAs for screening purposes in settings with relatively
low rates of TB infection could have several advantages over the TST beyond eliminating the
need of a return visit for reading. Having fewer patients test positive will result in a reduction
in needed resources (including personnel time) for the follow-up, evaluation, and treatment of
patients with suspected LTBI. The resources saved from the decrease in positivity could be
redirected to focus on ensuring those at highest risk for developing active TB initiate and com-
plete treatment. Furthermore, patients will not be unnecessarily exposed to medications or
Fig 1. From testing to treating LTBI in New York City Department of Health and Mental Hygiene chest clinics by QFT-G (2006–2008) or TST (2004–
2006). (a). Flowchart representing the flow of patients from testing to treatment for LTBI in the utilization periods (QFT-G and TST). Complete Evaluation:
evaluation by a physician and had a chest radiograph. Incomplete Evaluation: patients who were evaluated by a physician or had a chest radiograph but
not both. LTBI Treatment Completion: 9 months of isoniazid or completion of an alternative regimen, per ATS/CDC and NYC DOHMH guidelines at that
time. (b) Comparison of final LTBI test results, treatment initiation, and treatment outcomes between the utilization periods (QFT-G and TST). The bars
represent (from left to right) the percentage of patients who tested positive for LTBI; of patients who tested positive, the percentage evaluated for LTBI
treatment; of those evaluated, the percentage that had an indication for treatment; percentage of patients with treatment indication who initiated treatment for
LTBI; percentage that completed treatment for LTBI among those who had an indication, and the percentage that completed treatment among all those with
an indication for treatment who started treatment. [*] P<0.001, [**] P<0.0001
doi:10.1371/journal.pone.0138349.g001
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burdened with the difficulties associated with additional clinic visits. Increasing LTBI treat-
ment completion will result in prevention of future TB cases, making IGRAs a potentially more
cost-effective strategy for TB prevention than the TST [33–35].
Among patients with an indication for treatment, we found the proportion that initiated
treatment for LTBI was significantly increased during the QFT-G testing period. The sensitivity
analysis indicates that this result is marginally significant and may be dependent on exclusion
Table 1. Baseline characteristics of persons undergoing testing for LTBI during QFT-G (2006–2008) and TST (2004–2006) utilization in New York
City Department of Health and Mental Hygiene chest clinics.a
QFT-G TST
(N = 36,167) (N = 38,547)
N % N %
Sex
Female 19,511 54 21,493 56
Male 16,656 46 17,054 44
Age group (years)
1–4 237 1 482 1
5–9 1,142 3 682 2
10–14 2,997 8 1,860 5
15–19 4,973 14 4,622 12
20–49 22,973 64 26,600 69
50–65 3,415 9 3,835 10
>65 430 1 466 1
Race/Ethnicity
Non-Hispanic white 4,501 12 4,785 12
Hispanic (Any) 10,707 30 12,496 32
Non-Hispanic black 14,705 41 16,329 42
Asian 4,558 13 3,212 8
Otherb 1,696 5 1,725 4
Country of birthc
US 18,982 52 22,446 58
Non-US 17,185 48 16,041 42
Time in US (foreign-born only)c
0–1 years 5,632 33 5,250 33
1–5 years 3,257 19 2,785 17
>5 years 8,296 49 8,005 50
Primary Language
English 23,895 66 28,159 73
Non-English 12,272 34 10,388 27
Contact to Active TB Cased
Yes 1,182 3 1,152 3
No 34,985 97 37,395 97
QFT-G = QuantiFERON-TB Gold, TST = tuberculin skin test
a Excludes 2205 patients who had both TST and QFT-G performed
b Includes Native American, Pacific Islander
c 60 patients were missing a country of birth and 1 foreign-born patient was missing time in the US.
d Contacts were those exposed to a patient with infectious TB disease and were tested as part of a NYC DOHMH contact investigation. Non-contacts
included patients tested for any other reason
doi:10.1371/journal.pone.0138349.t001
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Table 2. LTBI treatment completion among patients with an indication for LTBI treatment, New York City Department of Health and Mental Hygiene





(N = 1,700) (N = 3,547)
N % N % aRRQ/T
e
Test Type
QFT-G 490 40 740 60 1.75 (1.49–2.06)
TST 1,210 30 2,807 70 Ref
Sex
Female 853 32 1821 68 —
Male 847 33 1726 67 —
Age group (years)
1–4 7 33 14 67 2.31 (1.44–3.72)
5–9 35 50 35 50 3.19 (2.30–4.44)
10–14 170 45 209 55 2.99 (2.33–3.85)
15–19 353 39 555 61 2.52 (1.93–3.29)
20–49 962 30 2,198 70 2.05 (1.72–2.46)
50–65 160 25 469 75 1.73 (1.37–2.18)
>65 13 16 67 84 Ref
Race/Ethnicity
Non-Hispanic white 64 22 223 78 Ref
Hispanic (Any) 658 35 1,235 65 1.41 (1.22–1.64)
Non-Hispanic black 458 26 1,281 74 1.22 (0.93–1.59)
Asian 443 42 620 58 1.63 (1.39–1.90)
Othera 77 29 188 71 1.29 (1.07–1.57)
Country of birthb
US 222 24 711 76 Ref
Foreign 1477 34 2834 66 1.18 (1.01–1.38)
Time in US (foreign-born only)b
0–1 years 637 38 1020 62 Ref
1–5 years 371 36 674 65 0.95 (0.87–1.06)
>5years 469 29 1,140 71 0.81 (0.74–0.90)
Primary Language
English 668 27 1,808 73 Ref
Non-English 1,032 37 1,739 63 1.13 (1.05–1.22)
Contact to an active TB case
Yes 170 45 212 56 1.35 (1.14–1.59)
No 1,530 31 3,335 69 Ref
QFT-G = QuantiFERON-TB Gold, TST = tuberculin skin test
a Excludes 2205 patients who had both TST and QFT-G performed
b Includes Native American, Pacific Islander
c 60 patients were missing a country of birth and 1 foreign-born patient was missing time in the US.
d Contacts were those exposed to a patient with infectious TB disease and were tested as part of a NYC DOHMH contact investigation. Non-contacts
included patients tested for any other reason.
e Estimates of relative risk were adjusted for age at test, reason for test, primary language (English, not English), birth in the US, race/ethnicity and year
that the test was performed. Sex was excluded based on the results of the bivariate analysis.
doi:10.1371/journal.pone.0138349.t002
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criteria based on the patient’s evaluation. Interestingly, we identified that a lower proportion of
persons had completed the necessary follow-up evaluation after testing positive with QFT-G
than during the historical control period (73% vs. 83%). This is likely because, when a patient’s
TST was read as positive, they received a chest radiograph and medical examination the same
day, whereas, with QFT-G patients with a positive test were contacted and asked to return for
further evaluation.
The improvement in the proportion of those who completed LTBI treatment after diagnosis
with QFT-G compared to TST has been documented in other studies as well. Grinsdale et al.
found that among TB contacts, both initiation and completion of treatment were improved
among those tested using QFT-G compared to TST [16]. Similar to our results, Shah et al.
found that there was no association between treatment initiation and test type, but unlike our
study they also did not find any impact on treatment completion [17]. This study also included
non-contacts, suggesting that there may be differential effects on treatment uptake and adher-
ence depending on patient and/or provider’s assessment of TB disease risk and/or biases asso-
ciated with testing strategy (i.e. providers may be more apt to “believe” a positive IGRA as
compared to TST). Associations between perceived risk (on the part of the patient) and adher-
ence to screening or treatment have been demonstrated for a wide variety of conditions [36–
38]. Our current study is unable to provide further insight into the reasons why completion
rates may be higher after a positive IGRA test result.
This study has several limitations. This analysis was done in the context of a TB control pro-
gram; therefore, we were only able to compare LTBI treatment initiation and completion
among patients tested with QFT-G to a historical group tested with TST and other programs
initiated by the NYC DOHMH aimed at increasing LTBI treatment completion could not be
taken directly into account though our model did contain a time term to address this. Further-
more, no information was available as to determine why patients were not fully evaluated or if
they were considered to have or not have an indication for LTBI treatment a priori. However,
there were no major changes in policy at the NYC Bureau of TB Control chest clinics during
the study period that would have substantially affected indication for LTBI treatment or the
regimens used. Second, data on BCG vaccination status, HIV status, and other comorbidities
and risk factors, which have been demonstrated to be related to LTBI treatment outcomes, was
not available for analysis [12]. Third, this study was conducted before utilization of the newly
recommended short course LTBI treatment regimen [39] which may have important impacts
on both uptake and adherence so that percentages initiating and completing treatment from
our study may not reflect those that would have been seen with the shorter regimen though
this is likely not to have differed by test type. Fourth, because DOT is not the standard of care
for LTBI treatment, we do not have verification that patients actually took their medication.
However, since patients needed to return monthly to obtain medication, those documented as
completing treatment most likely did so. Finally, we did not have information on patient and
healthcare provider beliefs and attitudes about LTBI and its treatment, including why LTBI
treatment was refused. Strengths of this analysis include a large, population-based study popu-
lation, a diverse patient population, and data was obtained from a “real world” setting. While
the large sample size may have resulted in an “over-powered” analysis we believe the differ-
ences demonstrated in treatment completion reflect clinically meaningful (as well as statisti-
cally significant) differences.
In summary, routine use of IGRAs for LTBI testing could have important public health
implications including increased provider and patient acceptance of LTBI diagnosis and treat-
ment and considerable cost savings due to their improved operating characteristics. Future
work should include prospective studies evaluating patient and provider attitudes, beliefs, and
their association with LTBI treatment outcomes and LTBI treatment outcomes associated with
LTBI Treatment: QFT-G vs. TST
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newer treatment regimens [39]. In addition, interventions targeted at specific high-risk groups
will likely be needed if improved rates of treatment success are to be realized.
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